

Matthew J Maurer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3289469/publications.pdf>

Version: 2024-02-01

278
papers

11,197
citations

41258

49
h-index

33814

99
g-index

278
all docs

278
docs citations

278
times ranked

14114
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. <i>Blood Advances</i> , 2022, 6, 1350-1360.	2.5	9
2	Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. <i>Blood Cancer Journal</i> , 2022, 12, 1.	2.8	7
3	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. <i>Blood Advances</i> , 2022, 6, 2745-2756.	2.5	3
4	Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121009038.	1.6	6
5	Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. <i>Lancet Haematology</i> , 2022, 9, e289-e300.	2.2	24
6	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. <i>Blood Cancer Journal</i> , 2022, 12, 78.	2.8	1
7	Therapy for patients with POD24 follicular lymphoma: Treatment patterns and outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7573-7573.	0.8	0
8	Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. <i>Blood Advances</i> , 2022, 6, 5210-5221.	2.5	2
9	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , 2021, 35, 522-533.	3.3	28
10	Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors. <i>Leukemia and Lymphoma</i> , 2021, 62, 247-251.	0.6	8
11	The association of health behaviors with quality of life in lymphoma survivors. <i>Leukemia and Lymphoma</i> , 2021, 62, 271-280.	0.6	6
12	Testicular ^{FDG}PET</sup>/^{CT} uptake threshold in aggressive lymphomas. <i>American Journal of Hematology</i> , 2021, 96, E81-E83.	2.0	3
13	Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 520-529.	0.6	10
14	JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis. <i>Blood Cancer Journal</i> , 2021, 11, 56.	2.8	3
15	The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. <i>Haematologica</i> , 2021, 106, 2261-2264.	1.7	0
16	Relapsed/Refractory International Prognostic Index (R^RIPI</sup>): An international prognostic calculator for relapsed/refractory diffuse large B^{cell} lymphoma. <i>American Journal of Hematology</i> , 2021, 96, 599-605.	2.0	8
17	Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting. <i>Scientific Reports</i> , 2021, 11, 8076.	1.6	9
18	Reversing the restrictive trend in diffuse large B^{cell} lymphoma trial eligibility: it's time to open the gates!. <i>British Journal of Haematology</i> , 2021, 193, 697-698.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy.. Journal of Clinical Oncology, 2021, 39, 8049-8049.	0.8	1
20	Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2021, 39, e13569-e13569.	0.8	1
21	Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. Journal of Clinical Oncology, 2021, 39, 1641-1649.	0.8	16
22	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. American Journal of Hematology, 2021, 96, 979-988.	2.0	5
23	Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. Blood Advances, 2021, 5, 2426-2437.	2.5	24
24	Body mass index and survival of patients with lymphoma. Leukemia and Lymphoma, 2021, 62, 2671-2678.	0.6	5
25	Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. Cancer, 2021, 127, 3390-3402.	2.0	6
26	Aortic Stenosis Progression, Cardiac Damage, and Survival. JACC: Cardiovascular Imaging, 2021, 14, 1113-1126.	2.3	26
27	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. Blood Cancer Journal, 2021, 11, 133.	2.8	4
28	Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. HemaSphere, 2021, 5, e640.	1.2	7
29	Cardiac Scintigraphy and Screening for Transthyretin Cardiac Amyloidosis. Circulation, 2021, 144, 1005-1007.	1.6	8
30	Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. American Journal of Surgical Pathology, 2021, 45, 384-393.	2.1	10
31	Cardiovascular Diseases That Have Emerged From the Darkness. Journal of the American Heart Association, 2021, 10, e021095.	1.6	5
32	Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. Blood, 2021, 138, 1327-1327.	0.6	0
33	High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. Blood, 2021, 138, 181-181.	0.6	14
34	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab. Blood, 2021, 138, 3517-3517.	0.6	1
35	Vaccination History and Risk of Lymphoma and Its Major Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0383.2021.	1.1	1
36	Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CART Consortium. Blood, 2021, 138, 744-744.	0.6	15

#	ARTICLE	IF	CITATIONS
37	Mismatch-Repair Deficiency in Follicular Lymphoma Tumors Is Common and Associated with a Favorable Overall Survival. <i>Blood</i> , 2021, 138, 3523-3523.	0.6	0
38	CHFR and Paclitaxel Sensitivity of Ovarian Cancer. <i>Cancers</i> , 2021, 13, 6043.	1.7	0
39	Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 878-878.	0.6	3
40	The Impact of Trial Eligibility Criteria on Outcomes in a Nationwide Cohort of Newly Diagnosed DLBCL Patients Treated with R-CHOP. <i>Blood</i> , 2021, 138, 53-53.	0.6	1
41	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. <i>Blood</i> , 2021, 138, 2429-2429.	0.6	1
42	Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium. <i>Blood</i> , 2021, 138, 3527-3527.	0.6	1
43	Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis. <i>Blood</i> , 2021, 138, 338-338.	0.6	0
44	Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes. <i>Blood</i> , 2021, 138, 2524-2524.	0.6	1
45	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. <i>Blood</i> , 2021, 138, 2508-2508.	0.6	0
46	Integration of Tumor Transcriptomic, Genomic, and Immune Profiles Reveals Distinct Populations of Low-Grade B-Cell Lymphomas with Poor Outcome. <i>Blood</i> , 2021, 138, 808-808.	0.6	0
47	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. <i>Blood</i> , 2021, 138, 2527-2527.	0.6	3
48	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 1221-1228.	2.9	22
49	Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. <i>Cancer</i> , 2020, 126, 894-907.	2.0	54
50	Compliance with cancer screening and influenza vaccination guidelines in non-Hodgkin lymphoma survivors. <i>Journal of Cancer Survivorship</i> , 2020, 14, 316-321.	1.5	5
51	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020, 10, 117.	2.8	18
52	Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent. <i>Blood</i> , 2020, 135, 1008-1018.	0.6	12
53	Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: <sc>CALGB</sc>/Alliance 50403. <i>American Journal of Hematology</i> , 2020, 95, 583-593.	2.0	18
54	The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3397-3407.	3.2	45

#	ARTICLE	IF	CITATIONS
55	High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?. Blood Cancer Journal, 2020, 10, 5.	2.8	22
56	Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma. Oncologist, 2020, 25, 689-695.	1.9	7
57	Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. British Journal of Haematology, 2020, 189, 661-671.	1.2	12
58	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. Blood, 2020, 136, 7-8.	0.6	2
59	Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis. Blood, 2020, 136, 35-36.	0.6	1
60	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. Blood, 2020, 136, 21-22.	0.6	0
61	Body Mass Index and Survival of Patients with Lymphoma. Blood, 2020, 136, 2-3.	0.6	0
62	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. Blood, 2020, 136, 36-37.	0.6	0
63	The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma. Blood, 2020, 136, 39-40.	0.6	0
64	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 26-27.	0.6	1
65	Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas. Blood, 2020, 136, 15-16.	0.6	0
66	Association of elevated serum free light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood Cancer Journal, 2019, 9, 59.	2.8	9
67	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood, 2019, 134, 1289-1297.	0.6	26
68	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 73.	2.8	37
69	53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecologic Oncology, 2019, 153, 127-134.	0.6	56
70	Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. Journal of Clinical Oncology, 2019, 37, 1819-1827.	0.8	44
71	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. British Journal of Haematology, 2019, 186, 820-828.	1.2	12
72	ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Haematologica, 2019, 104, e562-e565.	1.7	38

#	ARTICLE	IF	CITATIONS
73	Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 786-793.	2.0	15
74	Host genetic variation in tumor necrosis factor and nuclear factor- κ B pathways and overall survival in mantle cell lymphoma: A discovery and replication study. <i>American Journal of Hematology</i> , 2019, 94, E153-E155.	2.0	1
75	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. <i>American Journal of Hematology</i> , 2019, 94, 658-666.	2.0	19
76	Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. <i>British Journal of Haematology</i> , 2019, 186, e24-e27.	1.2	15
77	Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 144-152.	0.8	142
78	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019, 37, 1790-1799.	0.8	266
79	POD24 in MZL: a means to an end or an end point in itself?. <i>Blood</i> , 2019, 134, 787-788.	0.6	4
80	Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A. <i>PLoS ONE</i> , 2019, 14, e0224564.	1.1	6
81	Pre-treatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy. <i>Clinical Epidemiology</i> , 2019, Volume 11, 987-996.	1.5	5
82	Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 524-535.	1.2	27
83	Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma. <i>American Journal of Hematology</i> , 2019, 94, E62-E64.	2.0	15
84	Reply to the letter to the editor "Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting" by van der Galiën et al.. <i>Annals of Oncology</i> , 2019, 30, 153.	0.6	0
85	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC). <i>Blood</i> , 2019, 134, 400-400.	0.6	2
86	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019, 134, 72-72.	0.6	2
87	Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium. <i>Blood</i> , 2019, 134, 763-763.	0.6	42
88	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2019, 134, 69-69.	0.6	9
89	Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2896-2896.	0.6	2
90	Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients. <i>Blood</i> , 2019, 134, 5215-5215.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 919-919.	0.6	0
92	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. <i>Blood</i> , 2019, 134, 923-923.	0.6	0
93	Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era. <i>Blood</i> , 2019, 134, 422-422.	0.6	0
94	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018, 93, 57-68.	1.3	90
95	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	0.6	130
96	Online Physician Reviews Do Not Reflect Patient Satisfaction Survey Responses. <i>Mayo Clinic Proceedings</i> , 2018, 93, 453-457.	1.4	37
97	Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. <i>Blood Cancer Journal</i> , 2018, 8, 26.	2.8	92
98	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <i>MYC</i> predicts patient outcome in two independent cohorts. <i>British Journal of Haematology</i> , 2018, 180, 286-290.	1.2	13
99	Variability of performance status assessment between patients with hematologic malignancies and their physicians. <i>Leukemia and Lymphoma</i> , 2018, 59, 695-701.	0.6	11
100	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. <i>British Journal of Haematology</i> , 2018, 183, 149-152.	1.2	5
101	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. <i>Haematologica</i> , 2018, 103, 297-303.	1.7	17
102	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	0.8	93
103	Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma. <i>Blood Cancer Journal</i> , 2018, 8, 110.	2.8	22
104	Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?. <i>Nutrition and Cancer</i> , 2018, 70, 1088-1090.	0.9	4
105	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2018, 8, 97.	2.8	36
106	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018, 93, 1543-1550.	2.0	16
107	Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1123-1132.	3.0	83
108	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , 2018, 182, 644-653.	1.2	20

#	ARTICLE	IF	CITATIONS
109	History of autoimmune conditions and lymphoma prognosis. <i>Blood Cancer Journal</i> , 2018, 8, 73.	2.8	26
110	Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. <i>Hematological Oncology</i> , 2018, 36, 749-756.	0.8	13
111	Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. <i>Haematologica</i> , 2018, 103, 1899-1907.	1.7	52
112	Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. <i>Annals of Oncology</i> , 2018, 29, 1822-1827.	0.6	61
113	Association of Health Behaviors and Quality of Life in Lymphoma Survivors. <i>Blood</i> , 2018, 132, 4838-4838.	0.6	3
114	Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance). <i>Blood</i> , 2018, 132, 146-146.	0.6	6
115	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2018, 132, 454-454.	0.6	1
116	Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD). <i>Blood</i> , 2018, 132, 456-456.	0.6	4
117	Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. <i>Blood</i> , 2018, 132, 4204-4204.	0.6	1
118	Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10042-10042.	0.8	1
119	Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas. <i>Blood</i> , 2018, 132, 5401-5401.	0.6	1
120	Compliance with Age-Appropriate Screening for Malignancies and Influenza Vaccination in 3-Year Lymphoma Survivors. <i>Blood</i> , 2018, 132, 4791-4791.	0.6	0
121	Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. <i>Blood</i> , 2018, 132, 2979-2979.	0.6	0
122	Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era. <i>Blood</i> , 2018, 132, 4140-4140.	0.6	0
123	<i>FCGR3A</i> / <i>2A</i> polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	0.8	9
124	Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. <i>Clinical Cancer Research</i> , 2017, 23, 3794-3801.	3.2	103
125	Transthoracic Echocardiography versus Computed Tomography for Ascending Aortic Measurements in Patients with Bicuspid Aortic Valve. <i>Journal of the American Society of Echocardiography</i> , 2017, 30, 625-635.	1.2	31
126	Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 752-758.	2.0	23

#	ARTICLE	IF	CITATIONS
127	Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes. <i>Clinical Cancer Research</i> , 2017, 23, 4077-4085.	3.2	80
128	Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma – tissue remains the issue. <i>Leukemia and Lymphoma</i> , 2017, 58, 2342-2348.	0.6	10
129	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i.	0.9	57
130	Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab. <i>American Journal of Hematology</i> , 2017, 92, 1156-1162.	2.0	8
131	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. <i>Blood</i> , 2017, 130, 1800-1808.	0.6	1,084
132	Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	1.2	49
133	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 4019-4026.	0.8	50
134	Changes in Quality of Life in Indolent Non-Hodgkin Lymphoma 3 Years after Diagnosis. <i>Blood</i> , 2017, 130, 917-917.	0.6	4
135	EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review. <i>Genes and Cancer</i> , 2017, 8, 589-599.	0.6	45
136	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	2.0	41
137	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	2.0	180
138	Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, 776-781.	2.0	14
139	APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 4746-4755.	3.2	59
140	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 1104-1104.	0.6	1
141	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). <i>Blood</i> , 2016, 128, 155-155.	0.6	1
142	Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements". <i>Blood</i> , 2016, 128, 1750-1750.	0.6	2
143	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1874-1874.	0.6	2
144	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. <i>Blood</i> , 2016, 128, 3027-3027.	0.6	5

#	ARTICLE	IF	CITATIONS
145	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016, 128, 3034-3034.	0.6	5
146	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3035-3035.	0.6	5
147	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. <i>Blood</i> , 2016, 128, 5299-5299.	0.6	1
148	Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study. <i>Blood</i> , 2016, 128, 3036-3036.	0.6	0
149	An International Assessment of Event-Free Survival at 24 Months (EFS24) and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 920-920.	0.6	0
150	No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era. <i>Blood</i> , 2016, 128, 107-107.	0.6	0
151	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2935-2935.	0.6	0
152	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF- κ B positive feedback loop in peripheral T-cell lymphoma. <i>Blood</i> , 2015, 125, 3118-3127.	0.6	68
153	Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. <i>Blood</i> , 2015, 125, 992-998.	0.6	47
154	Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. <i>American Journal of Hematology</i> , 2015, 90, 790-795.	2.0	221
155	Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic. <i>Gynecologic Oncology</i> , 2015, 137, 77-85.	0.6	15
156	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2516-2522.	0.8	610
157	Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. <i>Gynecologic Oncology</i> , 2015, 137, 14-22.	0.6	79
158	Plasma immune analytes in patients with epithelial ovarian cancer. <i>Cytokine</i> , 2015, 73, 108-113.	1.4	31
159	Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1495-1504.	2.0	51
160	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3930-3937.	0.8	24
161	Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors. <i>Leukemia and Lymphoma</i> , 2015, 56, 434-439.	0.6	14
162	Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer. <i>Cancer Research</i> , 2015, 75, 22-30.	0.4	157

#	ARTICLE	IF	CITATIONS
163	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2683-2683.	0.6	6
164	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015, 126, 3992-3992.	0.6	1
165	QOL at 3 years after diagnosis in aggressive lymphoma survivors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9586-9586.	0.8	2
166	Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. <i>Oncotarget</i> , 2015, 6, 9488-9501.	0.8	42
167	Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. <i>Oncotarget</i> , 2015, 6, 35737-35754.	0.8	23
168	Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 131-131.	0.6	0
169	Tissue Is the Issue: Accuracy of PET Imaging to Detect Bone Marrow Clearance in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3947-3947.	0.6	0
170	Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3885-3885.	0.6	0
171	Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 1501-1501.	0.6	0
172	Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015, 126, 1456-1456.	0.6	0
173	Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 1116-1120.	2.0	16
174	Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein 10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 417-422.	2.0	18
175	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2014, 38, 768-775.	2.1	44
176	Large-Scale Evaluation of Common Variation in Regulatory T Cell-Related Genes and Ovarian Cancer Outcome. <i>Cancer Immunology Research</i> , 2014, 2, 332-340.	1.6	21
177	Tumorgrafts as <i>In Vivo</i> Surrogates for Women with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1288-1297.	3.2	168
178	Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 639-645.	2.0	26
179	Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3506-3512.	0.8	144
180	PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data. <i>Bioinformatics</i> , 2014, 30, 2678-2680.	1.8	43

#	ARTICLE	IF	CITATIONS
181	Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 1066-1073.	0.8	304
182	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , 2014, 124, 1473-1480.	0.6	401
183	Elevated soluble $IL-2R^{\pm}$, $IL-8$, and $MIP-1^2$ levels are associated with inferior outcome and are independent of $MIP-1$ score in patients with mantle cell lymphoma. <i>American Journal of Hematology</i> , 2014, 89, E223-7.	2.0	36
184	CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1475-1484.	2.0	28
185	Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Journal of Clinical Oncology</i> , 2013, 31, 3272-3278.	0.8	259
186	Survival Prediction Based on Inherited Gene Variation Analysis. <i>Methods in Molecular Biology</i> , 2013, 1049, 53-64.	0.4	1
187	The potential of serum light chains in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1857-1858.	0.6	1
188	Utility of Progranulin and Serum Leukocyte Protease Inhibitor as Diagnostic and Prognostic Biomarkers in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1730-1735.	1.1	33
189	Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts. <i>Cytokine</i> , 2013, 64, 523-531.	1.4	16
190	$FCGR2A$ and $FCGR3A$ polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status. <i>Leukemia and Lymphoma</i> , 2013, 54, 2571-2573.	0.6	7
191	APOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2013, 73, 7222-7231.	0.4	153
192	The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 290-297.	0.6	58
193	Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 6812-6819.	3.2	64
194	A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and ^{90}Y ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 589-593.	2.0	33
195	The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer. <i>PLoS ONE</i> , 2013, 8, e80063.	1.1	171
196	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. <i>Blood</i> , 2013, 122, 362-362.	0.6	2
197	In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy. <i>Blood</i> , 2013, 122, 844-844.	0.6	5
198	Inherited Variants in Regulatory T Cell Genes and Outcome of Ovarian Cancer. <i>PLoS ONE</i> , 2013, 8, e53903.	1.1	20

#	ARTICLE	IF	CITATIONS
199	Whole-Exome Analysis Of DLBCL Tumors Reveals a Unique Genetic Signature Associated With Aggressive Disease. <i>Blood</i> , 2013, 122, 499-499.	0.6	2
200	Elevated Soluble IL-2Ra Levels Are Associated With Inferior Outcome and Is Independent Of MIPI Score in Patients With Mantle Cell Lymphoma. <i>Blood</i> , 2013, 122, 4256-4256.	0.6	0
201	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. <i>Blood</i> , 2013, 122, 76-76.	0.6	1
202	Variability Of Performance Status Assessment Between Patients With Hematologic Malignancies and Their Physicians. <i>Blood</i> , 2013, 122, 1703-1703.	0.6	0
203	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. <i>Blood</i> , 2013, 122, 1774-1774.	0.6	0
204	LIM domain only 2 protein expression, <i>LMO2</i> germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. <i>Leukemia and Lymphoma</i> , 2012, 53, 1105-1112.	0.6	5
205	Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. <i>Modern Pathology</i> , 2012, 25, 651-660.	2.9	66
206	Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. <i>Blood</i> , 2012, 120, 4400-4406.	0.6	53
207	Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinic-based case-control study. <i>Cytokine</i> , 2012, 60, 882-889.	1.4	50
208	Inherited genetic variation and overall survival following follicular lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 724-726.	2.0	13
209	Elevated pretreatment serum levels of interferon-inducible protein 10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. <i>American Journal of Hematology</i> , 2012, 87, 865-869.	2.0	37
210	Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 880-885.	2.0	36
211	Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. <i>Blood</i> , 2012, 119, 2844-2853.	0.6	149
212	Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population. <i>Blood</i> , 2012, 120, 1540-1540.	0.6	2
213	Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource. <i>Blood</i> , 2012, 120, 1546-1546.	0.6	1
214	EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (âˆ“) Counterparts: Results From University of Iowa/Mayo Clinic SPORE. <i>Blood</i> , 2012, 120, 1604-1604.	0.6	1
215	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2012, 120, 684-684.	0.6	0
216	Expression of MYC but Not pSTAT3 Is an Adverse Prognostic Factor for Diffuse Large B Cell Lymphoma (DLBCL) Treated with Epratuzumab/R-CHOP. <i>Blood</i> , 2012, 120, 1575-1575.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project. <i>Blood</i> , 2012, 120, 1545-1545.	0.6	6
218	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. <i>Blood</i> , 2012, 120, 149-149.	0.6	0
219	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. <i>Blood</i> , 2012, 120, 1563-1563.	0.6	0
220	Host Genetics and Risk of Cardiovascular Disease in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. <i>Blood</i> , 2012, 120, 1573-1573.	0.6	0
221	Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes.. <i>Blood</i> , 2012, 120, 2655-2655.	0.6	0
222	Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies. <i>Blood</i> , 2012, 120, 3637-3637.	0.6	0
223	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. <i>Blood</i> , 2012, 120, 2702-2702.	0.6	0
224	Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 118, 4053-4061.	0.6	136
225	Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. <i>Haematologica</i> , 2011, 96, 1619-1626.	1.7	37
226	Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 1492-1498.	0.6	110
227	Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. <i>Blood</i> , 2011, 118, 4882-4889.	0.6	37
228	Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 2821-2826.	0.6	50
229	Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2011, 86, 998-1000.	2.0	28
230	Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1620-1626.	0.8	70
231	Cardiac Outcomes in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. <i>Blood</i> , 2011, 118, 2656-2656.	0.6	26
232	Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. <i>Blood</i> , 2011, 118, 429-429.	0.6	1
233	Elevated Serum IL-10 Levels in Patients with Diffuse Large B Cell Lymphoma: A Mechanism of Aberrant JAK2 Kinase Activation. <i>Blood</i> , 2011, 118, 960-960.	0.6	0
234	Elevated Monoclonal Free Light Chains Are a Serum Marker of ABC Type Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2011, 118, 1591-1591.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 245-52.	0.4	7
236	Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 161-171.	2.0	12
237	Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 2993-3000.	2.0	68
238	Expression of LMO2 Is Associated With t(14;18)/IGH-BCL2 Fusion but Not BCL6 Translocations in Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2010, 134, 278-281.	0.4	8
239	Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2010, 28, 412-417.	0.8	75
240	Inherited Determinants of Ovarian Cancer Survival. <i>Clinical Cancer Research</i> , 2010, 16, 995-1007.	3.2	56
241	Reply to J.R. Carver et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e612-e612.	0.8	0
242	Reply to C. Barker et al and H. Asai et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e427-e428.	0.8	0
243	A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a Novel In vivo Immunodominant Epitope, HER-2/neu88-102. <i>Clinical Cancer Research</i> , 2010, 16, 825-834.	3.2	15
244	Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4191-4198.	0.8	184
245	18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of "indeterminate" reports. <i>Leukemia and Lymphoma</i> , 2010, 51, 439-446.	0.6	21
246	Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 996-996.	0.6	2
247	Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. <i>Blood</i> , 2010, 116, 991-991.	0.6	1
248	Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 2052-2058.	0.8	323
249	Complementary and alternative medicine use among long-term lymphoma survivors: A pilot study. <i>American Journal of Hematology</i> , 2009, 84, 795-798.	2.0	49
250	PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 137-137.	0.6	5
251	Vitamin D Deficiency Is Associated with Inferior Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 1952-1952.	0.6	0
252	MYC Translocations Are Associated with Poor Overall Survival in DLBCL Patients in Both the Chemotherapy and Immunochemotherapy Eras.. <i>Blood</i> , 2009, 114, 443-443.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma.. Blood, 2009, 114, 440-440.	0.6	4
254	A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma. Cancer, 2008, 112, 1772-1779.	2.0	19
255	Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma. Cancer, 2008, 113, 508-514.	2.0	220
256	An HLA-DR*4 Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2-Specific Immunity in Patients with Cancer. Cancer Research, 2008, 68, 4893-4901.	0.4	16
257	A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma. Clinical Cancer Research, 2008, 14, 6697-6703.	3.2	149
258	Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood, 2008, 112, 2694-2702.	0.6	64
259	Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood, 2007, 109, 5439-5446.	0.6	109
260	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).. Blood, 2007, 110, 121-121.	0.6	31
261	Host Genetic Variation in the Cell Cycle and NF- κ B Pathways and Overall Survival in Mantle Cell Lymphoma.. Blood, 2007, 110, 1582-1582.	0.6	0
262	Polymorphisms in One-Carbon Metabolism Genes and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2007, 110, 1568-1568.	0.6	1
263	A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).. Blood, 2007, 110, 124-124.	0.6	2
264	Prospective Study of Quality of Life in Adults with Newly Diagnosed High-grade Gliomas. Journal of Neuro-Oncology, 2006, 76, 283-291.	1.4	161
265	A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer, 2006, 107, 2826-2832.	2.0	44
266	Validation of neuroradiologic response assessment in gliomas: Measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods1. Neuro-Oncology, 2006, 8, 156-165.	0.6	117
267	Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients. Clinical Cancer Research, 2006, 12, 6056-6063.	3.2	52
268	Germline Single Nucleotide Polymorphisms (SNPs) in IL1A, IL6, IL10, and IFNGR2 in Combination with Clinical with Demographic Factors Predict Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2006, 108, 2028-2028.	0.6	0
269	Smoking, Obesity and Overall Survival in Non-Hodgkin Lymphoma (NHL): A Population-Based Study.. Blood, 2006, 108, 4649-4649.	0.6	0
270	Cytokine Gene Polymorphisms and Overall Survival in Follicular Lymphoma: Results from a Large Population-Based Study.. Blood, 2006, 108, 820-820.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Host Immunogenetic Single Nucleotide Polymorphisms (SNPs) Predict Overall Survival in Small Lymphocytic Lymphoma.. Blood, 2006, 108, 2396-2396.	0.6	0
272	A Prospective Study of Quality of Life in Adults with Newly Diagnosed High-grade Gliomas: The Impact of the Extent of Resection on Quality of Life and Survival. Neurosurgery, 2005, 57, 495-504.	0.6	186
273	Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): Results of North Central Cancer Treatment Group trial 98-72-51. International Journal of Radiation Oncology Biology Physics, 2005, 61, 380-386.	0.4	13
274	Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes and Cancer, 2005, 42, 68-77.	1.5	89
275	Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial. Investigational New Drugs, 2005, 23, 495-503.	1.2	20
276	Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology, 2005, 23, 5294-5304.	0.8	688
277	Clinical trials in lymphoma. , 0, , 45-60.		0
278	Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis. JCO Oncology Practice, 0, , .	1.4	0